Key Highlights

  • Simulations Plus reported US$24.3mn Revenue (+8%), beating consensus estimates.
  • Software gross Margin held at 89%, supporting overall Margin expansion to 66%.
  • AI partnerships with pharma firms signal future growth potential beyond FY2026.

Simulations Plus, Inc. (Nasdaq: SLP), a US-based provider of model-informed Drug Development software and consulting services, has delivered a second-quarter fiscal 2026 result that captured both the resilience of its core software Franchise and the early-stage strategic shift toward artificial intelligence-led offerings. Revenue of US$24.3 million grew 8 per cent year-on-year and exceeded the consensus forecast of US$21.66 million, while adjusted Earnings Per Share of US$0.35 beat the consensus estimate of US$0.31.

Behind the headline beat sits a company in transition: continuing to Leverage its long-standing software platforms used across the Drug Development life cycle, while initiating multiple strategic AI collaborations with large pharmaceutical companies and recalibrating expectations for when those AI initiatives are likely to contribute meaningfully to the Top Line.

Company background

Founded in 1996 and headquartered in Lancaster, California, Simulations Plus develops and licenses biosimulation software and provides associated consulting services used by pharmaceutical, biotechnology, food, chemical and regulatory customers. Its portfolio includes platforms for physiologically based pharmacokinetic (PBPK) modelling, quantitative systems pharmacology, population pharmacokinetics and other model-informed Drug Development applications.

The company organises its Revenue around two principal categories: software, which provides higher-Margin recurring licence Revenue, and services, which include consulting, modelling and other professional engagements that complement the software Franchise.

Simulations Plus is listed on the Nasdaq Capital Market under the ticker SLP. Its fiscal year ends in late August, with the company recently reporting results for its second fiscal quarter ended in late February 2026.

Latest developments

Simulations Plus' second-quarter fiscal 2026 results, released in early April, showed Revenue of US$24.3 million, up 8 per cent year-on-year. Performance came in above the company's own top-line guidance and beat the consensus expectation. Adjusted Earnings Per Share of US$0.35 also exceeded consensus, reflecting both Revenue growth and continued cost discipline.

Margin performance was a notable element of the quarter. Adjusted EBITDA of US$8.7 million represented a Margin of approximately 36 per cent, while gross Margin expanded to 66 per cent, including software gross Margin of 89 per cent and services gross Margin of 33 per cent. The total gross Margin compared favourably with 59 per cent in the prior-year period, with mix shift toward higher-Margin software and improved services execution contributing to the improvement.

Strategically, the most significant update centred on artificial intelligence. Management noted ongoing strategic collaboration programmes with three large pharmaceutical companies focused on advancing AI workflows across the Drug Development life cycle. While these partnerships are positioned as important medium-term growth drivers, management indicated that fiscal 2027 was the more likely period for AI-related contribution to begin meaningfully affecting the Top Line.

On the financial outlook, Simulations Plus maintained a full-year fiscal 2026 Revenue guidance range of US$79 million to US$82 million, implying growth of 0 to 4 per cent for the year, with software mix expected between 57 and 62 per cent. Adjusted EBITDA Margin guidance of 26 to 30 per cent and adjusted diluted EPS of US$0.75 to US$0.85 were maintained, although the company noted a higher effective tax rate as a headwind to reported EPS.

Balance-sheet metrics remained strong. The company reported cash and short-term investments of US$41.8 million, with no Debt, providing flexibility to invest in product development, AI capabilities, and selective acquisitions.

Recent financial performance

The Q2 fiscal 2026 financial profile illustrated both the strength of the company's software Franchise and the more cyclical nature of its services Business. Software Revenue continued to benefit from recurring licence arrangements and the deep integration of Simulations Plus tools into customer drug-development workflows. Services Revenue performance reflected a broader mix of project-based and consulting engagements, where clinical activity and customer prioritisation can affect quarterly cadence.

The improvement in gross Margin to 66 per cent was supported by mix shift, software pricing dynamics and stronger services execution. The 89 per cent software gross Margin reflected the inherent profitability of the licensed-software model when delivered at scale.

Operating expenses continued to scale with the company's strategic priorities, including Investment in product development, expansion of the salesforce and the early-stage build-out of AI capabilities. Adjusted EBITDA Margin of 36 per cent was healthy by industry standards, illustrating the operating Leverage available to the Business at the current Revenue base.

Cash Flow generation has supported continued Investment in R&D, complementary acquisitions over time and a measured approach to Capital management. With no Debt and a sizeable cash position, the company has financial flexibility to navigate cyclical pressures and capitalise on selective opportunities, including potential AI-related investments and product extensions.

Share-market context

SLP shares trade on the Nasdaq and have historically been viewed as a way to gain exposure to specialty biosimulation software within the broader life sciences and healthcare technology landscape. The stock has reacted to a familiar set of catalysts: quarterly results, software versus services mix, customer commentary, AI-related announcements and broader sentiment toward small- and mid-cap healthcare technology.

Following the Q2 fiscal 2026 release, market commentary highlighted the headline beat, the strength of software margins and the ongoing transition toward AI partnerships, alongside the more measured full-year Revenue growth outlook of 0 to 4 per cent. The combination of strong margins and modest near-term Revenue growth has framed an Investment narrative focused on both the durability of the software Franchise and the potential for AI-driven monetisation in fiscal 2027 and beyond.

Macro factors — including pharmaceutical and biotechnology R&D spending, regulatory dynamics, and broader sentiment toward small- and mid-cap healthcare technology — continue to influence price action. The relatively small float and specialist nature of the Business contribute to share-price sensitivity around individual data points.

Industry backdrop

The pharmaceutical and biotechnology industry continues to be a major customer base for biosimulation software and services. Pharmaceutical R&D spending, while subject to cyclical pressures, remains a multi-trillion-dollar global activity, with model-informed Drug Development tools playing a growing role in early-stage research, regulatory submissions and lifecycle management.

Within model-informed Drug Development, regulatory agencies — including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) — have continued to recognise the role of biosimulation in supporting Drug Development decisions. This has supported the broad-based adoption of PBPK and related modelling approaches across the industry.

AI applications in Drug Development have emerged as a major theme. From target identification to clinical trial design, optimisation of dosing regimens and lifecycle management, AI is increasingly seen as a way to improve productivity and decision-making. Biosimulation companies, including Simulations Plus, have positioned themselves at the intersection of mechanistic modelling and machine-learning approaches.

Competition spans large diversified life-sciences technology providers, specialty biosimulation peers, contract research organisations offering modelling services, and emerging AI-led entrants. Maintaining technology differentiation, customer relationships and regulatory relevance is critical to long-term competitiveness.

Strategy and growth drivers

Simulations Plus' strategy is anchored in several themes: extending Leadership in model-informed Drug Development software, scaling the services Franchise to support customer projects, deepening regulatory engagement and developing AI-led capabilities to expand its addressable market.

Within software, continued Investment in PBPK platforms, quantitative systems pharmacology, population pharmacokinetics and related modelling tools is expected to support both renewals and new licences. The high gross Margin of the software Franchise underscores the strategic importance of this segment.

On the services side, the company has continued to invest in its consulting and modelling teams, with the goal of supporting both customer outcomes and pull-through of software adoption. Services Revenue can be variable quarter to quarter, but supports the broader customer relationship and provides insight into emerging customer needs.

The AI initiative is positioned as a strategic priority. Strategic collaborations with three large pharmaceutical companies are designed to advance AI workflows across the drug-development life cycle. While management has indicated that meaningful AI-driven Revenue contribution is more likely from fiscal 2027 onwards, the early partnerships represent important validation points and learning opportunities.

Capital allocation continues to balance Investment in R&D, opportunistic M&A and a strong Balance Sheet, with the company historically maintaining a conservative financial posture.

Customer engagement extends across global pharmaceutical companies, biotechnology firms, generics manufacturers, contract research organisations, regulators and academic centres. The breadth of the customer base reflects the broad applicability of model-informed Drug Development across early discovery, clinical development and regulatory submission stages, and supports a diversified Revenue base across multiple therapeutic areas.

Risks and challenges

Simulations Plus faces several risks. Customer concentration within pharmaceutical and biotechnology customers, while diversified across many companies, remains relevant. Cyclical pressures in pharmaceutical R&D budgets, particularly during periods of broader biotech funding stress, can affect both software renewals and services Demand.

Execution risk is significant in the AI initiative. The successful design, validation and commercialisation of AI workflows across Drug Development requires substantial Investment, scientific rigour and customer commitment. Outcomes and timelines can shift, as suggested by management's emphasis on fiscal 2027 for meaningful AI Revenue contribution.

Competitive risk is broad. Large life-sciences technology companies, specialty biosimulation peers, CROs and AI-led startups all compete for share. Maintaining technology and regulatory Leadership requires continued Investment.

Regulatory and scientific risk includes evolving regulatory expectations for model-informed Drug Development and the credibility of new methodologies. Talent risk is also relevant, given the specialised nature of biosimulation, statistical modelling and AI capabilities.

Other risks include intellectual property considerations, Cybersecurity exposure given the sensitivity of customer data, and execution risk around acquisitions and integration of new capabilities.

Analyst and investor focus

Investors and analysts will likely focus on a clear set of indicators going forward. Software Revenue trajectory and software gross Margin will remain central markers of the durability of the Franchise. Services Revenue patterns, including timing of customer projects, will provide additional context.

Adjusted EBITDA Margin within the 26 to 30 per cent guidance range, alongside adjusted diluted EPS performance, will help shape views on through-cycle profitability. Updates on the AI initiative — including the progress of strategic collaborations, additional partnerships and any quantification of Revenue contribution potential — will influence sentiment.

Balance-sheet flexibility, Capital deployment activity and any updates on M&A or Investment in adjacent capabilities will continue to be watched. Commentary on pharmaceutical and biotechnology spending dynamics, regulatory trends and broader life-sciences technology themes will help shape the medium-term narrative.

Outlook

Over the next 12 to 24 months, Simulations Plus' performance is likely to be shaped by the trajectory of pharmaceutical R&D spending, the pace of AI initiative progress and the continued execution of the company's software and services franchises. The fiscal 2026 Revenue growth range of 0 to 4 per cent reflects a measured near-term outlook, while the AI partnerships are positioned to begin contributing more meaningfully in fiscal 2027.

Margin trajectory will be a meaningful indicator. Continued strength in software margins, alongside disciplined services execution, is expected to support adjusted EBITDA performance. Investment in AI and other strategic initiatives may affect Operating Expense trajectory, although management has continued to emphasise Margin discipline.

Capital allocation will remain central, with the strong Balance Sheet providing flexibility for organic and inorganic Investment alongside disciplined cost management.

Beyond the core pharmaceutical end market, the company has historically explored opportunities in adjacent regulated industries — including specific food, chemical and consumer-product applications — where mechanistic and statistical modelling can support safety, formulation and regulatory work. These adjacencies, while smaller in scale, contribute to the breadth of the long-term opportunity set.

Conclusion

Simulations Plus' second-quarter fiscal 2026 result combined a top- and bottom-line beat with strong software margins and a clear strategic narrative around AI partnerships. The company's positioning at the intersection of model-informed Drug Development and emerging AI workflows offers multiple potential growth levers, although near-term Revenue growth remains measured. Issues investors are likely to monitor include software and services Revenue trajectory, gross and adjusted EBITDA Margin performance, AI initiative milestones, Capital management activity and the broader environment for pharmaceutical R&D spending.